MindWalk (HYFT) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 FY2025 was CAD 5.3 million, down 7.5% year-over-year, with double-digit growth at Victoria and Oss sites and a net loss of CAD 4 million compared to CAD 3.4 million in the prior year.

• Fee-for-service drug discovery saw a surge in VHH antibody programs and robust B-Cell Select activity, with 25 new programs initiated across the last two quarters.

• AI-driven LENS.ai platform and BioStrand's HYFT technology are central to strategy, enabling faster, more efficient antibody discovery and optimization.

• Strategic focus on licensing AI-optimized therapeutic candidates, with milestone and royalty structures to drive both short-term and long-term value.

• Cash on hand was CAD 4 million as of July 31, 2024, but is insufficient to fund operations for a full year, raising substantial doubt about going concern status.

Financial highlights

• Revenue of CAD 5.3 million in Q1 FY2025, a 7.5% decrease year-over-year but a 12% increase over Q1 FY2023, mainly due to lower project and product sales at the Utrecht site.

• Net loss of CAD 4 million (CAD 0.15 per share) versus CAD 3.4 million (CAD 0.14 per share) in Q1 FY2024, reflecting increased R&D and commercialization spend.

• Gross profit margin declined to 45% from 49% due to lower revenue and higher costs from expansion and inflation.

• R&D expenses rose to CAD 1.6 million from CAD 0.9 million year-over-year, driven by LENS.ai rollout.

• Cash balance at quarter-end was CAD 4 million, with CAD 3 million in net financings completed during the quarter.

Outlook and guidance

• Strong demand for antibody discovery and development services continues, with a robust weighted pipeline for fee-for-service work at BioStrand.

• Management emphasizes the need to raise additional funds to support operations and strategic growth, with no assurance of sufficient financing.

• AI-driven LENS.ai platform expected to further enhance efficiency and revenue streams.

• Anticipation of macroeconomic tailwinds as interest rates potentially decrease, benefiting biotech and microcap sectors.

• Market trends indicate growing demand for external CRO partners and AI-driven drug discovery, supporting the company’s strategic direction.